ReviewJournal of cellular and molecular medicine2019
The pathological role of Wnt5a in psoriasis and psoriatic arthritis.
Review in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Deciphering the association between Sirt2 modulation and non-canonical Wnt/planar cell polarity-dependent splenic junctional priming: a comparative study of two Sirt2 modulators in murine endotoxemia.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Causal Associations Between Chronic Inflammatory Skin Diseases and Alzheimer's Disease: A Bidirectional Two-Sample Mendelian Randomization Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Topical MTH1 Inhibition Suppresses SKP2-WNT5a-Driven Psoriatic Hyperproliferation.International journal of molecular sciences · 2025Article
- Identification of miR-190a-5p and miR-26b-5p as Potential microRNA Biomarkers for Psoriatic Arthritis.ACR open rheumatology · 2025Article
- Role of miRNAs in the pathogenesis of psoriasis and psoriatic arthritis: a genome-wide Mendelian randomization study.Clinical rheumatology · 2025Article
- Multiscale Dissection of Spatial Heterogeneity by Integrating Multi-Slice Spatial and Single-Cell Transcriptomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Wnt signaling as a translational target in rheumatoid and psoriatic arthritis.Journal of translational medicine · 2025Article
- Triptolide alleviates psoriasis through inhibiting the Wnt5a/β-Catenin signaling pathway.Frontiers in pharmacology · 2025Article
- Momordin Ic ameliorates psoriasis skin damage in mice via the IL-23/IL-17 axis.Archives of dermatological research · 2024Article
- Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis.Journal of personalized medicine · 2024Review
- Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade.Nature communications · 2024Article
- Associations of Wnt5a expression with liver injury in chronic hepatitis B virus infection.BMC infectious diseases · 2023Article
- Convergent deployment of ancestral functions during the evolution of mammalian flight membranes.Science advances · 2023Article
- Article
- Wnt Signaling Pathways: From Inflammation to Non-Melanoma Skin Cancers.International journal of molecular sciences · 2023Review
- A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis.Frontiers in immunology · 2023Article
- Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications.Nature reviews. Cardiology · 2022Review
- SimulatedPostepy dermatologii i alergologii · 2022Article
- Contribution of the Environment, Epigenetic Mechanisms and Non-Coding RNAs in Psoriasis.Biomedicines · 2022Review
- TNF-α Activating Osteoclasts in Patients with Psoriatic Arthritis Enhances the Recruitment of Osteoclast Precursors: A Plausible Role of WNT5A-MCP-1 in Osteoclast Engagement in Psoriatic Arthritis.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis (PsO) is a chronic inflammatory skin disease with both local and systemic components. PsO-associated arthritis, known as psoriatic arthritis (PsA), develops in approximately 13%-25% of PsO patients. Various factors associated with both PsO and PsA indicate that these conditions are part of a single disease. Identification of novel targets for the development of drugs to treat both PsO and PsA is desirable to provide more patient-friendly treatment regimens. Such targets will likely represent 'common checkpoints' of inflammation, for example key components or transduction cascades of the signalling pathways involved. Emerging evidence supports involvement of the non-canonical Wnt signalling pathways in the development of both PsO and PsA, especially the Wnt5a-activated signalling cascades. These, together with interlinked factors, are crucial in the interactions among keratinocytes, immune cells and inflammatory factors in PsO, as well as among chondrocytes, osteoblasts and osteoclasts that trigger both subchondral bone remodelling and cartilage catabolism in PsA. This review focuses on the pathological role of Wnt5a signalling and its interaction with other interlinked pathways in both PsO and PsA, and also on the main challenges for future research, particularly with respect to molecules targeting Wnt signalling pathways for the treatment of PsO and PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.